327 related articles for article (PubMed ID: 31821457)
1. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Kastritis E; Roussou M; Gavriatopoulou M; Kanellias N; Migkou M; Eleutherakis-Papaiakovou E; Ziogas DC; Fotiou D; Ntanasis-Stathopoulos I; Dialoupi I; Giannouli S; Tsirigotis P; Delimpasi S; Mparmparousi D; Spyropoulou-Vlachou M; Xirokosta A; Terpos E; Dimopoulos MA
Blood Adv; 2019 Dec; 3(23):4095-4103. PubMed ID: 31821457
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
3. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Scott LJ
Drugs; 2014 Apr; 74(5):549-62. PubMed ID: 24590685
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
Siegel DS; Schiller GJ; Samaras C; Sebag M; Berdeja J; Ganguly S; Matous J; Song K; Seet CS; Talamo G; Acosta-Rivera M; Bar M; Quick D; Anz B; Fonseca G; Reece D; Pierceall WE; Chung W; Zafar F; Agarwal A; Bahlis NJ
Leukemia; 2020 Dec; 34(12):3286-3297. PubMed ID: 32376855
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
Siegel DS; Schiller GJ; Song KW; Agajanian R; Stockerl-Goldstein K; Kaya H; Sebag M; Samaras C; Malek E; Talamo G; Seet CS; Mouro J; Pierceall WE; Zafar F; Chung W; Srinivasan S; Agarwal A; Bahlis NJ
Br J Haematol; 2020 Feb; 188(4):501-510. PubMed ID: 31588567
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; McCurdy A; Song K; LeBlanc R; Sebag M; White D; Cherniawsky H; Reiman A; Stakiw J; Louzada ML; Kotb R; Aslam M; Gul E; Venner CP
Eur J Haematol; 2021 Oct; 107(4):416-427. PubMed ID: 34129703
[TBL] [Abstract][Full Text] [Related]
10. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
[TBL] [Abstract][Full Text] [Related]
12. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
13. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
Zagouri F; Roussou M; Kastritis E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Kalapanida D; Christoulas D; Migkou M; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2016 Aug; 57(8):1776-80. PubMed ID: 26916452
[TBL] [Abstract][Full Text] [Related]
15. Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment.
Oriol A; Dimopoulos M; Schjesvold F; Beksac M; Facon T; Dhanasiri S; Guo S; Mu Y; Hong K; Gentili C; Galli M; Yagci M; Larocca A; Richardson P; Weisel K
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):165-176.e4. PubMed ID: 38072743
[TBL] [Abstract][Full Text] [Related]
16. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Dimopoulos M; Weisel K; Moreau P; Anderson LD; White D; San-Miguel J; Sonneveld P; Engelhardt M; Jenner M; Corso A; Dürig J; Pavic M; Salomo M; Casal E; Srinivasan S; Yu X; Nguyen TV; Biyukov T; Peluso T; Richardson P
Leukemia; 2021 Jun; 35(6):1722-1731. PubMed ID: 32895455
[TBL] [Abstract][Full Text] [Related]
17. Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma.
Mark T; Falkenstein A; Kish J
Future Oncol; 2022 Feb; 18(5):553-564. PubMed ID: 34787472
[TBL] [Abstract][Full Text] [Related]
18. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial.
Kumar S; Sharma A; Malik PS; Gogia A; Pathak N; Sahoo RK; Gupta R; Prasad CP; Kumar L
Br J Haematol; 2022 Jul; 198(2):288-297. PubMed ID: 35499209
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
